ImmunoScape

ImmunoScape ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic.

ImmunoScape is a clinical biotechcompany transforming cancer therapy with our novel Seed-and-Boost Approach -
A combination therapy delivering superior anti-tumor efficacy at dramatically lower cost. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically

relevant TCRs across multiple types of solid tumors. To learn more, visit us at immunoscape.com and follow us on Twitter .

We are proud to announce the ex*****on of a Memorandum of Understanding (MOU) with a premier NCI-designated U.S. Compreh...
10/03/2026

We are proud to announce the ex*****on of a Memorandum of Understanding (MOU) with a premier NCI-designated U.S. Comprehensive Cancer Center to fast-track our "Seed and Boost" platform into the clinic. This collaboration will launch an investigator-initiated clinical trial targeting WT1-positive solid tumors, including ovarian, mesothelioma, pancreatic, and colorectal cancers, with first patient dosing expected by September 2026.

Concurrently, we are thrilled to welcome Leonardo DiCaprio as a strategic investor, supporting the development of our next-generation TCR-based cancer immunotherapies.

Our "Seed and Boost" approach is designed to address the persistence and exhaustion challenges seen in traditional cell therapies:
The Seed: Autologous T-cells engineered with high-affinity TCR targeting WT1
The Boost: Immuno-STAT™ technology to selectively expand and activate WT1-targeting T-cells in patients

This announcement marks a significant step in our mission to bring innovative, life-changing therapies to patients with difficult-to-treat solid tumors.

ImmunoScape announced an MOU with a premier NCI-designated Comprehensive Cancer Center in the US and a strategic investment from Leonardo DiCaprio

ImmunoScape Pte. Ltd., an A*STAR - Agency for Science, Technology and Research spin out backed by Amgen Ventures and EDB...
10/03/2026

ImmunoScape Pte. Ltd., an A*STAR - Agency for Science, Technology and Research spin out backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies is thrilled and pleased to announced an exclusive in-licensing deal with Cue Biopharma to lead the development of a distinct new class of therapies to attack solid tumor cancers. The deal provides ImmunoScape with exclusive access to Cue Biopharma’s clinical-stage Immuno-STAT® molecules in oncology.
In line with our transition in cancer immunotherapy development, ImmunoScape is pleased to announce additions to its leadership structure.

“Seed-and-Boost” Approach with Breakthrough Potential, Poised to Transform the Cancer Immunotherapy Landscape SINGAPORE — ImmunoScape Pte. Ltd., an A*STAR spin out backed by Amgen Ventures and EDBi that is developing next-generation TCR-based cancer immunotherapies, today announced an exclusiv...

10/03/2026

We are excited to announce a strategic collaboration and exclusive licensing agreement with Cue Biopharma to advance a novel in vivo T-cell expansion Seed-and-Boost approach for solid tumor therapy. By combining Cue’s clinically validated CUE-100 series T-cell engagers with our next-generation tumor-specific TCRs, we aim to drive more durable and scalable cell therapy outcomes for patients.

https://cuebiopharma.gcs-web.com/node/10161/pdf?utm_source=organicsocial&utm_medium=LI&utm_campaign=immunoscape-pr

Address


Website

Alerts

Be the first to know and let us send you an email when ImmunoScape posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to ImmunoScape:

Shortcuts

  • Want your business to be the top-listed Engineering Company?

Share